Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Símbolo de cotizaciónMANE
Nombre de la empresaVeradermics Inc
Fecha de salida a bolsaFeb 04, 2026
Director ejecutivoWaldman (Reid Alexander)
Número de empleados19
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 04
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónMANE
Fecha de salida a bolsaFeb 04, 2026
Director ejecutivoWaldman (Reid Alexander)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos